A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database

2018 ◽  
Vol 17 (12) ◽  
pp. 1161-1169 ◽  
Author(s):  
Carla Carnovale ◽  
Faizan Mazhar ◽  
Marco Pozzi ◽  
Marta Gentili ◽  
Emilio Clementi ◽  
...  
2019 ◽  
Vol 14 (1) ◽  
pp. 21-26 ◽  
Author(s):  
Viswam Subeesh ◽  
Eswaran Maheswari ◽  
Hemendra Singh ◽  
Thomas Elsa Beulah ◽  
Ann Mary Swaroop

Background: The signal is defined as “reported information on a possible causal relationship between an adverse event and a drug, of which the relationship is unknown or incompletely documented previously”. Objective: To detect novel adverse events of iloperidone by disproportionality analysis in FDA database of Adverse Event Reporting System (FAERS) using Data Mining Algorithms (DMAs). Methodology: The US FAERS database consists of 1028 iloperidone associated Drug Event Combinations (DECs) which were reported from 2010 Q1 to 2016 Q3. We consider DECs for disproportionality analysis only if a minimum of ten reports are present in database for the given adverse event and which were not detected earlier (in clinical trials). Two data mining algorithms, namely, Reporting Odds Ratio (ROR) and Information Component (IC) were applied retrospectively in the aforementioned time period. A value of ROR-1.96SE>1 and IC- 2SD>0 were considered as the threshold for positive signal. Results: The mean age of the patients of iloperidone associated events was found to be 44years [95% CI: 36-51], nevertheless age was not mentioned in twenty-one reports. The data mining algorithms exhibited positive signal for akathisia (ROR-1.96SE=43.15, IC-2SD=2.99), dyskinesia (21.24, 3.06), peripheral oedema (6.67,1.08), priapism (425.7,9.09) and sexual dysfunction (26.6-1.5) upon analysis as those were well above the pre-set threshold. Conclusion: Iloperidone associated five potential signals were generated by data mining in the FDA AERS database. The result requires an integration of further clinical surveillance for the quantification and validation of possible risks for the adverse events reported of iloperidone.


2021 ◽  
Vol 10 (2) ◽  
pp. 20-24
Author(s):  
Chenthamarai.G ◽  
Lakshmi Prasanna.T.

Introduction: Mirtazapine is an antidepressant drug that produces both noradrenergic and serotonergic activity. It is effective in treating of mild to severe depression. Proper evidence pointing to the safety of Mirtazapine is not established. The need for post-marketing surveillance (PMS) is considered most essential. This study was aimed to generate signal for unreported adverse drug reactions for Mirtazapine.  Materials and Methods: Our study retrospectively analyzed the AEs reported entered in the Adverse Events Reporting System (FAERS) databases in the last 10-years during the period of Jan 2011 to June 2020. Disproportionality analysis was done using Reporting Odds Ratio, Proportional Reporting Ratio, and Information Component with 95% confidence interval. Results: A disproportionality analysis was done for 41 adverse events, out of these, signal for 11 adverse events was found. ROR values 10.17 being the highest for abulia and 2.22 being the lowest for homicidal Ideation. The PRR value was 10.17 being the highest for abulia and 2.22 being the lowest for homicidal ideation. The IC025 value was 1.87 for abulia and 0.27 for homicidal Ideation. Conclusion: The present study using the Adverse Events Reporting System (FAERS) databases maintained by the FDA suggested new safety signals for Mirtazapine. Still more cohort and epidemiological studies are recommended to validate these results. Keywords: Mirtazapine, Disproportionality analysis, Safety Signals.


Jurnal NERS ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. 133
Author(s):  
Apriyani Puji Hastuti ◽  
Nursalam Nursalam ◽  
Mira Triharini

Introductions: Medication error is one of many types of errors that could decrease the quality and safety of healthcare. Increasing number of adverse events (AE) reflects the number of medication errors. This study aimed to develop a model of medication error prevention based on knowledge management. This model is expected to improve knowledge and skill of nurses to prevent medication error which is characterized by the decrease of adverse events (AE). Methods: This study consisted of two stages. The first stage of research was an explanative survey using cross-sectional approach involving 15 respondents selected by purposive sampling. The second stage was a pre-test experiment involving 29 respondents selected with cluster sampling. Partial Leas square (PLS) was used to examine the factors affecting medication error prevention model while the Wilcoxon Signed Rank Test was used to test the effect of medication error prevention model against adverse events (AE). Results: Individual factors (path coefficient 12:56, t = 4,761) play an important role in nurse behavioral changes about medication error prevention based in knowledge management, organizational factor (path coefficient = 0276, t = 2.504) play an important role in nurse behavioral changes about medication error prevention based on knowledge management. Work characteristic factor (path coefficient = 0309, t = 1.98) play an important role in nurse behavioral changes about medication error prevention based on knowledge management. The medication error prevention model based on knowledge management was also significantly decreased adverse event (p = 0.000, α <0.05). Discussion: Factors of individuals, organizations and work characteristics were important in the development of medication error prevention models based on knowledge management.


Sign in / Sign up

Export Citation Format

Share Document